Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Feb 23, 2023

Dr. Allen Davidoff is the Founder and CEO of XORTX Therapeutics, testing the benefit of a therapeutic for autosomal dominant polycystic kidney disease, a rare progressive kidney disease with a clear genetic connection. Evidence suggests that lowering the activity of the xanthine oxidase enzyme in the kidney and lowering uric acid production via this enzyme is critical to developing a therapy that can benefit these patients.

Allen explains, "In terms of real therapies that slow the progression of kidney disease, there are very few. And so, to take the example of the rare disease, autosomal dominant polycystic kidney disease, one drug is currently approved. It was approved in 2018, that's a drug called tolvaptan, but it's only really used in about 5% of individuals. So that leaves this rare disease population largely underserved despite the fact that there's an approved drug."

"The drug that we're developing is oxypurinol. It is a xanthine oxidase inhibitor that has been studied extensively over a number of years. It is arguably the single best-tolerated xanthine oxidase inhibitor that's never been to market. We've started with that drug and reformulated it in a proprietary way to deliver it so that it will reach circulating blood concentrations that can inhibit the xanthine oxidase enzyme by 90% or more."

@XORTXinc #ADPKD #PKD #ProgressiveKidneyDisease #KidneyHealth #RareDisease

Download the transcript here